Latest Period
Q1 2026
Security Snapshot
Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL) Institutional Ownership
CUSIP: 05280R100
13F Institutional Holders and Ownership History from Q2 2018 to Q1 2026
Institutions Reporting
84
Shares (Excl. Options)
134,436,091
Price
$1.38
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share
- Symbol
- AUTL on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 134,436,091
- Total 13F value
- $184,354,727
- Portfolio coverage rank
- 0%
- Share change
- -3,613,694
- Value change
- -$5,299,819
- Number of holders
- 84
- Shares outstanding
- 266,837,198
- SEC-reported price per share
- $1.60
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- AUTL - Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share is tracked under CUSIP 05280R100.
- 84 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 90 to 84 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $277,117,628 to $184,354,727.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 84 institutions filings for Q1 2026.
Security key
05280R100
Latest holder period
Q1 2026
13F holders
84
13D/G owners
5
CIK / CUSIP context first
Open Q1 2026 holders
AUTL full holder history
Autolus Therapeutics plc SEC filings
Autolus Therapeutics plc company facts
Autolus Therapeutics plc insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 05280R100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
AUTL
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| MAK Capital Fund LP | 13% | +12% | $49,423,586 | +$5,315,732 | 33,621,487 | +12% | MAK Capital Fund LP | 31 Mar 2026 |
| Syncona Portfolio Ltd | 11% | $37,755,579 | 28,821,053 | Syncona Portfolio Limited | 31 Mar 2025 | |||
| ARMISTICE CAPITAL, LLC | 5.9% | -9.1% | $23,226,000 | -$2,499,000 | 15,800,000 | -9.7% | Armistice Capital, LLC | 31 Mar 2026 |
| FMR LLC | 3.8% | $13,312,676 | 10,162,348 | FMR LLC | 31 Mar 2025 | |||
| Deep Track Capital, LP | 0.97% | $4,186,839 | 2,568,613 | Deep Track Capital, LP | 30 Sep 2025 |
As of 31 Mar 2026, 84 institutional investors reported holding 134,436,091 shares of Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL). This represents 50% of the company’s total 266,837,198 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
49%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| MAK CAPITAL ONE LLC | 13% | 33,621,487 | +12% | 7.7% | $46,397,652 |
| Blackstone Inc. | 7.7% | 20,485,611 | 0% | 0.12% | $28,270,143 |
| Syncona Portfolio Ltd | 6.2% | 16,640,720 | 0% | 89% | $22,964,194 |
| ARMISTICE CAPITAL, LLC | 5.9% | 15,800,000 | -9.7% | 0.72% | $21,804,000 |
| Tetragon Partners GP Ltd | 3.6% | 9,500,000 | 0% | 2.6% | $13,110,000 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 3.6% | 9,489,345 | 0% | 0.01% | $12,051,468 |
| Frazier Life Sciences Management, L.P. | 1.7% | 4,447,910 | -3.8% | 0.16% | $6,138,116 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.3% | 3,361,156 | 0% | 0.01% | $4,638,395 |
| Laurion Capital Management LP | 1.2% | 3,316,626 | 0% | 0.43% | $4,576,944 |
| RENAISSANCE TECHNOLOGIES LLC | 0.86% | 2,299,499 | -26% | 0% | $3,173,309 |
| BANK OF AMERICA CORP /DE/ | 0.69% | 1,844,671 | -5.9% | 0% | $2,545,646 |
| BlackRock, Inc. | 0.55% | 1,480,732 | -60% | 0% | $2,043,410 |
| UBS Group AG | 0.49% | 1,305,779 | +49% | 0% | $1,801,976 |
| Cetera Investment Advisers | 0.42% | 1,129,074 | +2.7% | 0% | $1,558,122 |
| Balyasny Asset Management L.P. | 0.36% | 971,691 | 0% | $1,340,934 | |
| MORGAN STANLEY | 0.35% | 941,823 | -33% | 0% | $1,299,716 |
| JPMORGAN CHASE & CO | 0.35% | 935,403 | -4.5% | 0% | $1,187,962 |
| Alphabet Inc. | 0.26% | 698,262 | 0% | 0.02% | $963,602 |
| Marex Group plc | 0.2% | 542,857 | 0.01% | $749,143 | |
| CITADEL ADVISORS LLC | 0.17% | 459,404 | -60% | 0% | $633,978 |
| Hennion & Walsh Asset Management, Inc. | 0.16% | 440,206 | -3% | 0.02% | $607,484 |
| Point72 Asset Management, L.P. | 0.16% | 426,983 | +40% | 0% | $589,237 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.15% | 399,143 | -33% | 0% | $550,817 |
| Privium Fund Management B.V. | 0.14% | 363,430 | +11% | 0.1% | $501,533 |
| EDENTREE ASSET MANAGEMENT Ltd | 0.11% | 300,000 | 0% | 0.13% | $414,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
32
Latest
Q1 2026
Rows shown
1-25 of 32
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 134,436,091 | $184,354,727 | -$5,299,819 | $1.38 | 84 |
| 2025 Q4 | 139,369,843 | $277,117,628 | -$1,857,316 | $1.99 | 90 |
| 2025 Q3 | 143,579,673 | $233,669,297 | -$67,552,879 | $1.63 | 95 |
| 2025 Q2 | 165,944,662 | $378,376,899 | +$9,844,394 | $2.28 | 93 |
| 2025 Q1 | 168,007,060 | $260,819,521 | -$3,531,773 | $1.55 | 93 |
| 2024 Q4 | 168,335,372 | $395,090,875 | -$37,054,930 | $2.35 | 107 |
| 2024 Q3 | 178,602,235 | $648,320,594 | +$2,536,180 | $3.63 | 97 |
| 2024 Q2 | 178,106,548 | $619,765,055 | -$54,511,638 | $3.48 | 106 |
| 2024 Q1 | 175,580,707 | $1,120,176,501 | +$380,385,653 | $6.38 | 114 |
| 2023 Q4 | 115,868,017 | $746,230,557 | +$30,259,044 | $6.44 | 97 |
| 2023 Q3 | 110,707,409 | $257,962,960 | +$2,926,164 | $2.33 | 67 |
| 2023 Q2 | 109,330,876 | $260,181,467 | +$12,434,850 | $2.38 | 67 |
| 2023 Q1 | 105,962,470 | $194,950,415 | -$3,026,243 | $1.84 | 64 |
| 2022 Q4 | 107,371,378 | $203,976,112 | +$109,842,474 | $1.90 | 69 |
| 2022 Q3 | 49,366,337 | $105,661,961 | -$3,352,319 | $2.14 | 62 |
| 2022 Q2 | 50,829,136 | $143,849,865 | -$7,115,566 | $2.83 | 57 |
| 2022 Q1 | 45,661,103 | $190,513,250 | -$17,791,387 | $4.17 | 60 |
| 2021 Q4 | 52,463,220 | $272,271,730 | +$101,855,863 | $5.19 | 69 |
| 2021 Q3 | 25,076,258 | $164,226,984 | -$2,136,433 | $6.55 | 55 |
| 2021 Q2 | 25,378,541 | $169,575,110 | +$23,313,452 | $6.64 | 64 |
| 2021 Q1 | 22,400,702 | $128,321,739 | +$53,655,759 | $5.73 | 58 |
| 2020 Q4 | 12,635,638 | $112,960,120 | +$962,285 | $8.94 | 46 |
| 2020 Q3 | 12,386,365 | $143,379,095 | -$24,849,875 | $11.64 | 44 |
| 2020 Q2 | 14,328,662 | $229,696,396 | -$16,435,312 | $16.03 | 48 |
| 2020 Q1 | 15,977,491 | $96,357,056 | +$6,942,585 | $5.99 | 50 |